EOLS Evolus Inc.

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.

$11.61  -0.61 (-4.99%)
As of 03/05/2021 15:58:54 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Drug Manufacturers—Specialty &
USA
USA
02/08/2018
33,749,228
2,735,755
$390,816,060
0.00%
SEC Edgar Online
10-Q
10-K
30052C107
US30052C1071
BDRJH21

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-5.85
11.13
7.05
-190.42%
-120.60%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy